Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-reple...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:285084 |
| Acceso en línea: | https://ddd.uab.cat/record/285084 https://dx.doi.org/urn:doi:10.1016/j.bbmt.2019.05.025 |
| Access Level: | acceso abierto |
| Palabra clave: | Allogeneic transplantation Alternative donor Haploidentical transplantation Hodgkin lymphoma |
| id |
ES_ff7253e4782c9800a8c8aca62cb902d0 |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:285084 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| title |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| spellingShingle |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma Ahmed, Sairah|||0000-0001-7302-8299 Allogeneic transplantation Alternative donor Haploidentical transplantation Hodgkin lymphoma |
| title_short |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| title_full |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| title_fullStr |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| title_full_unstemmed |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| title_sort |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma |
| dc.creator.none.fl_str_mv |
Ahmed, Sairah|||0000-0001-7302-8299 Kanakry, Jennifer A. Ahn, Kwang Woo|||0000-0003-4567-8037 Litovich, Carlos Alejandro Abdel-Azim, Hisham Aljurf, Mahmoud Deeb Bacher, Vera Ulrike Bejanyan, Nelli|||0000-0003-0194-7338 Cohen, Jonathon B. Farooq, Umar|||0000-0001-7891-9891 Fuchs, Ephraim Joseph Bolaños-Meade, Javier Ghosh, Nilanjan S. Herrera, Álex F.|||0000-0002-9665-7415 Hossain, Nasheed|||0000-0002-3278-655X Inwards, David|||0000-0002-6894-9277 Kanate, Abraham Sebastian Martino Bofarull, Rodrigo|||0000-0001-5143-4042 Munshi, Pashna|||0000-0002-8079-9443 Murthy, Hemant S.|||0000-0003-4534-4248 Mussetti, Alberto|||0000-0002-4088-036X Nieto, Yago|||0000-0001-6034-8939 Perales, Miguel-Angel|||0000-0002-5910-4571 Romee, Rizwan|||0000-0001-9077-4736 Savani, Bipin|||0000-0002-3304-9965 Seo, Sachiko|||0000-0002-4308-2152 Wirk, Baldeep Mona Yared, Jean A.. Sureda, Anna|||0000-0002-1238-6970 Fenske, Timothy S. Hamadani, Mehdi|||0000-0001-5372-510X |
| author |
Ahmed, Sairah|||0000-0001-7302-8299 |
| author_facet |
Ahmed, Sairah|||0000-0001-7302-8299 Kanakry, Jennifer A. Ahn, Kwang Woo|||0000-0003-4567-8037 Litovich, Carlos Alejandro Abdel-Azim, Hisham Aljurf, Mahmoud Deeb Bacher, Vera Ulrike Bejanyan, Nelli|||0000-0003-0194-7338 Cohen, Jonathon B. Farooq, Umar|||0000-0001-7891-9891 Fuchs, Ephraim Joseph Bolaños-Meade, Javier Ghosh, Nilanjan S. Herrera, Álex F.|||0000-0002-9665-7415 Hossain, Nasheed|||0000-0002-3278-655X Inwards, David|||0000-0002-6894-9277 Kanate, Abraham Sebastian Martino Bofarull, Rodrigo|||0000-0001-5143-4042 Munshi, Pashna|||0000-0002-8079-9443 Murthy, Hemant S.|||0000-0003-4534-4248 Mussetti, Alberto|||0000-0002-4088-036X Nieto, Yago|||0000-0001-6034-8939 Perales, Miguel-Angel|||0000-0002-5910-4571 Romee, Rizwan|||0000-0001-9077-4736 Savani, Bipin|||0000-0002-3304-9965 Seo, Sachiko|||0000-0002-4308-2152 Wirk, Baldeep Mona Yared, Jean A.. Sureda, Anna|||0000-0002-1238-6970 Fenske, Timothy S. Hamadani, Mehdi|||0000-0001-5372-510X |
| author_role |
author |
| author2 |
Kanakry, Jennifer A. Ahn, Kwang Woo|||0000-0003-4567-8037 Litovich, Carlos Alejandro Abdel-Azim, Hisham Aljurf, Mahmoud Deeb Bacher, Vera Ulrike Bejanyan, Nelli|||0000-0003-0194-7338 Cohen, Jonathon B. Farooq, Umar|||0000-0001-7891-9891 Fuchs, Ephraim Joseph Bolaños-Meade, Javier Ghosh, Nilanjan S. Herrera, Álex F.|||0000-0002-9665-7415 Hossain, Nasheed|||0000-0002-3278-655X Inwards, David|||0000-0002-6894-9277 Kanate, Abraham Sebastian Martino Bofarull, Rodrigo|||0000-0001-5143-4042 Munshi, Pashna|||0000-0002-8079-9443 Murthy, Hemant S.|||0000-0003-4534-4248 Mussetti, Alberto|||0000-0002-4088-036X Nieto, Yago|||0000-0001-6034-8939 Perales, Miguel-Angel|||0000-0002-5910-4571 Romee, Rizwan|||0000-0001-9077-4736 Savani, Bipin|||0000-0002-3304-9965 Seo, Sachiko|||0000-0002-4308-2152 Wirk, Baldeep Mona Yared, Jean A.. Sureda, Anna|||0000-0002-1238-6970 Fenske, Timothy S. Hamadani, Mehdi|||0000-0001-5372-510X |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universitat Autònoma de Barcelona |
| dc.subject.none.fl_str_mv |
Allogeneic transplantation Alternative donor Haploidentical transplantation Hodgkin lymphoma |
| topic |
Allogeneic transplantation Alternative donor Haploidentical transplantation Hodgkin lymphoma |
| description |
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first RIC allo-HCT for cHL between 2008 and 2016 using either a haplo-PTCy (n = 139) or MSD/CNI-based (n = 457) approach. Overall survival (OS) was the primary endpoint. Secondary endpoints included acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). On multivariate analysis, there was no significant difference between haplo/PTCy and MDS/CNI-based approaches in terms of OS (hazard ratio [HR], 1.07; 95% confidence interval [CI],.79 to 1.45; P =.66) or PFS (HR,.86; 95% CI,.68 to 1.10; P =.22). Haplo/PTCy was associated with a significantly higher risk of grades II to IV aGVHD (odds ratio [OR], 1.73, 95% CI, 1.16 to 2.59; P =.007), but the risk of grades III to IV aGVHD was not significantly different between the 2 cohorts (OR,.61; 95% CI,.29 to 1.27; P =.19). The haplo/PTCy platform provided a significant reduction in cGVHD risk (HR,.45; 95% CI,.32 to.64; P <.001), and a significant reduction in relapse risk (HR,.74; 95% CI,.56 to.97; P =.03). There was a statistically nonsignificant trend toward higher NRM with a haplo/PTCy approach (HR, 1.65; 95% CI,.99 to 2.77; P =.06). Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approaches. There was a leaning toward higher NRM with a haplo/PTCy-based platform. These data show that haplo/PTCy allo-HCT in cHL results in survival comparable with MSD/CNI-based allo-HCT. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2 2019-01-01 2019 2019-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/285084 https://dx.doi.org/urn:doi:10.1016/j.bbmt.2019.05.025 |
| url |
https://ddd.uab.cat/record/285084 https://dx.doi.org/urn:doi:10.1016/j.bbmt.2019.05.025 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869425775473590272 |
| spelling |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin LymphomaAhmed, Sairah|||0000-0001-7302-8299Kanakry, Jennifer A.Ahn, Kwang Woo|||0000-0003-4567-8037Litovich, Carlos AlejandroAbdel-Azim, HishamAljurf, Mahmoud DeebBacher, Vera UlrikeBejanyan, Nelli|||0000-0003-0194-7338Cohen, Jonathon B.Farooq, Umar|||0000-0001-7891-9891Fuchs, Ephraim JosephBolaños-Meade, JavierGhosh, Nilanjan S.Herrera, Álex F.|||0000-0002-9665-7415Hossain, Nasheed|||0000-0002-3278-655XInwards, David|||0000-0002-6894-9277Kanate, Abraham SebastianMartino Bofarull, Rodrigo|||0000-0001-5143-4042Munshi, Pashna|||0000-0002-8079-9443Murthy, Hemant S.|||0000-0003-4534-4248Mussetti, Alberto|||0000-0002-4088-036XNieto, Yago|||0000-0001-6034-8939Perales, Miguel-Angel|||0000-0002-5910-4571Romee, Rizwan|||0000-0001-9077-4736Savani, Bipin|||0000-0002-3304-9965Seo, Sachiko|||0000-0002-4308-2152Wirk, Baldeep MonaYared, Jean A..Sureda, Anna|||0000-0002-1238-6970Fenske, Timothy S.Hamadani, Mehdi|||0000-0001-5372-510XAllogeneic transplantationAlternative donorHaploidentical transplantationHodgkin lymphomaClassic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first RIC allo-HCT for cHL between 2008 and 2016 using either a haplo-PTCy (n = 139) or MSD/CNI-based (n = 457) approach. Overall survival (OS) was the primary endpoint. Secondary endpoints included acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). On multivariate analysis, there was no significant difference between haplo/PTCy and MDS/CNI-based approaches in terms of OS (hazard ratio [HR], 1.07; 95% confidence interval [CI],.79 to 1.45; P =.66) or PFS (HR,.86; 95% CI,.68 to 1.10; P =.22). Haplo/PTCy was associated with a significantly higher risk of grades II to IV aGVHD (odds ratio [OR], 1.73, 95% CI, 1.16 to 2.59; P =.007), but the risk of grades III to IV aGVHD was not significantly different between the 2 cohorts (OR,.61; 95% CI,.29 to 1.27; P =.19). The haplo/PTCy platform provided a significant reduction in cGVHD risk (HR,.45; 95% CI,.32 to.64; P <.001), and a significant reduction in relapse risk (HR,.74; 95% CI,.56 to.97; P =.03). There was a statistically nonsignificant trend toward higher NRM with a haplo/PTCy approach (HR, 1.65; 95% CI,.99 to 2.77; P =.06). Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approaches. There was a leaning toward higher NRM with a haplo/PTCy-based platform. These data show that haplo/PTCy allo-HCT in cHL results in survival comparable with MSD/CNI-based allo-HCT.Universitat Autònoma de Barcelona 22019-01-0120192019-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/285084https://dx.doi.org/urn:doi:10.1016/j.bbmt.2019.05.025reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2850842026-06-06T12:50:31Z |
| score |
15,300724 |